dc.contributor.author |
Braatvedt, Geoffrey |
en |
dc.contributor.author |
Cundy, Timothy |
en |
dc.contributor.author |
Crooke, M |
en |
dc.contributor.author |
Florkowski, C |
en |
dc.contributor.author |
Mann, JI |
en |
dc.contributor.author |
Lunt, H |
en |
dc.contributor.author |
Jackson, Rodney |
en |
dc.contributor.author |
Orr-Walker, B |
en |
dc.contributor.author |
Kenealy, Timothy |
en |
dc.contributor.author |
Drury, PL |
en |
dc.date.accessioned |
2015-01-22T23:07:52Z |
en |
dc.date.issued |
2012 |
en |
dc.identifier.citation |
New Zealand Medical Journal, 2012, 125 (1362), pp. 70 - 80 |
en |
dc.identifier.issn |
0028-8446 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/24238 |
en |
dc.description.abstract |
In New Zealand laboratories the measurement of glycated haemoglobin (HbA1c) for diagnosis of diabetes is now only reported in SI units of mmol/mol. HbA1c is now recommended as the preferred test to diagnose diabetes in most circumstances. The requirement for a second positive test in asymptomatic individuals is retained. An HbA1c ≥50 mmol/mol (repeated on a second occasion in asymptomatic patients) is diagnostic of diabetes and a value ≤40 mmol/mol represents normal glucose tolerance. For patients with an initial HbA1c result of 41–49 mmol/mol, cardiovascular risk assessment and lifestyle interventions are recommended with repeat HbA1c screening in 6–12 months. For patients whose HbA1c is ≤40 mmol/mol, repeat screening (including for CVD risk) at intermittent intervals is recommended as per published guidelines. |
en |
dc.publisher |
New Zealand Medical Association |
en |
dc.relation.ispartofseries |
New Zealand Medical Journal |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0028-8446/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Understanding the new HbA1c units for the diagnosis of Type 2 diabetes |
en |
dc.type |
Journal Article |
en |
pubs.issue |
1362 |
en |
pubs.begin-page |
70 |
en |
pubs.volume |
125 |
en |
dc.description.version |
VoR - Version of Record |
en |
dc.rights.holder |
Copyright:
New Zealand Medical Association |
en |
dc.identifier.pmid |
23178606 |
en |
pubs.author-url |
http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2012/vol-125-no-1362/article-braatvedt |
en |
pubs.end-page |
80 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
361231 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Population Health |
en |
pubs.org-id |
Epidemiology & Biostatistics |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Medicine Department |
en |
dc.identifier.eissn |
1175-8716 |
en |
pubs.record-created-at-source-date |
2012-09-25 |
en |
pubs.dimensions-id |
23178606 |
en |